Cargando…
An Elvitegravir Nanoformulation Crosses the Blood–Brain Barrier and Suppresses HIV-1 Replication in Microglia
Even with an efficient combination of antiretroviral therapy (ART), which significantly decreases viral load in human immunodeficiency virus type 1 (HIV-1)-positive individuals, the occurrence of HIV-1-associated neurocognitive disorders (HAND) still exists. Microglia have been shown to have a signi...
Autores principales: | Gong, Yuqing, Zhi, Kaining, Nagesh, Prashanth K. B., Sinha, Namita, Chowdhury, Pallabita, Chen, Hao, Gorantla, Santhi, Yallapu, Murali M., Kumar, Santosh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290679/ https://www.ncbi.nlm.nih.gov/pubmed/32443728 http://dx.doi.org/10.3390/v12050564 |
Ejemplares similares
-
Novel elvitegravir nanoformulation for drug delivery across the blood-brain barrier to achieve HIV-1 suppression in the CNS macrophages
por: Gong, Yuqing, et al.
Publicado: (2020) -
Novel elvitegravir nanoformulation approach to suppress the viral load in HIV-infected macrophages
por: Gong, Yuqing, et al.
Publicado: (2017) -
miRNA-205 Nanoformulation Sensitizes Prostate Cancer Cells to Chemotherapy
por: Nagesh, Prashanth K. B., et al.
Publicado: (2018) -
Development of polyvinylpyrrolidone/paclitaxel self-assemblies for breast cancer
por: Chowdhury, Pallabita, et al.
Publicado: (2018) -
Tannic Acid-Lung Fluid Assemblies Promote Interaction and Delivery of Drugs to Lung Cancer Cells
por: Hatami, Elham, et al.
Publicado: (2018)